Search results for " seizure"

showing 10 items of 81 documents

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

PRRT2 mutations are the major cause of benign familial infantile seizures.

2012

Mutations in PRRT2 have been described in paroxysmal kinesigenic dyskinesia (PKD) and infantile convulsions with choreoathetosis (PKD with infantile seizures), and recently also in some families with benign familial infantile seizures (BFIS) alone. We analyzed PRRT2 in 49 families and three sporadic cases with BFIS only of Italian, German, Turkish, and Japanese origin and identified the previously described mutation c.649dupC in an unstable series of nine cytosines to occur in 39 of our families and one sporadic case (77% of index cases). Furthermore, three novel mutations were found in three other families, whereas 17% of our index cases did not show PRRT2 mutations, including a large fami…

AdultMaleAdolescentChoreoathetosisNerve Tissue ProteinsBiologymedicine.disease_causeSeizures FebrileInfantile seizures03 medical and health sciencesEpilepsy0302 clinical medicineGeneticsmedicineHumansChildGenetics (clinical)030304 developmental biologyAgedGenetics0303 health sciencesMutationBenign familial infantile epilepsyEpilepsyPRRT2; EpilepsyInfantMembrane ProteinsParoxysmal dyskinesiaMiddle Agedmedicine.diseaseMajor genePedigreeChild PreschoolMutationPRRT2medicine.symptomSpasms Infantile030217 neurology & neurosurgeryPRRT2Human mutation
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

2011

Background:  To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Methods:  Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months). Results:  Fifteen of 38 patients (39.5%) had a ≥50% seizure reduction in co…

AdultMalePediatricsmedicine.medical_specialtyAdolescentrufinamideRufinamideIrritabilityrefractory seizures; rufinamide; epileptic encephalopathies-childhoodYoung AdultRefractoryepileptic encephalopathies-childhoodrefractory seizuresrufinamideMedicineHumansYoung adultAdverse effectChildPreschoolepileptic encephalopathies-childhoodBrain DiseasesEpilepsybusiness.industryEpileptic encephalopathies-childhood; Refractory seizures; RufinamideTriazolesmedicine.diseaseSettore MED/39 - Neuropsichiatria Infantilerefractory seizuresMigraineepileptic encephalopathies-childhood refractory seizures rufinamideNeurologyAnesthesiaChild PreschoolVomitingAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessEpileptic encephalopathies-childhood; Refractory seizures; Rufinamide; Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child Preschool; Epilepsy; Female; Humans; Male; Triazoles; Young Adult; Neurology (clinical); NeurologyLennox–Gastaut syndromemedicine.drug
researchProduct

Late seizures in cerebral venous thrombosis

2020

ObjectiveTo examine the incidence, characteristics, treatment, and predictors of late seizures (LS) after cerebral venous thrombosis (CVT), we described these features in a registry of 1,127 patients with CVT.MethodsWe included consecutive adult patients from an international consortium of 12 hospital-based CVT registries. We excluded patients with a history of epilepsy or with <8 days of follow-up. We defined LS as seizures occurring >7 days after diagnosis of CVT. We used multivariable Cox regression to identify predictors of LS.ResultsWe included 1,127 patients with CVT. During a median follow-up of 2.0 years (interquartile range [IQR] 1.0–6.3), 123 patients (11%) experienced ≥1 LS…

AdultMaleStatus epilepticus030204 cardiovascular system & hematology03 medical and health sciencesEpilepsy0302 clinical medicineRecurrenceRisk FactorsSeizuresInterquartile rangemedicineHumansStrokeVenous ThrombosisIntracerebral hemorrhagebusiness.industryIncidenceHazard ratiocerebral venous thrombosisSymptomatic seizuresMiddle Agedmedicine.disease3. Good healthVenous thrombosisAnesthesiaFemaleSettore MED/26 - NeurologiaNeurology (clinical)Intracranial Thrombosismedicine.symptombusiness030217 neurology & neurosurgeryNeurology
researchProduct

Alcohol-related seizures may be associated with more severe depression, alcohol dependence syndrome, and more pronounced alcohol-related problems.

2018

Severe alcohol abuse and related medical and social functioning risks, as well as clinically significant depression, are common in patients who are admitted to hospital with alcohol-related seizures (ARS) and significantly affect the quality of life of the patient. Compared with studies involving patients with alcohol dependence, no large-scale studies with the aim of finding the prevalence and severity of depression and its most commonly affected aspects for patients with ARS have been carried out in Latvia yet. The habits and frequency of alcohol use in correlation to depression and its severity are also not known. One hundred ten patients were included in the study - 60 patients with ARS…

AdultMalemedicine.medical_specialtyAlcohol DrinkingPopulationAlcohol abuseAlcohol use disorderAffect (psychology)Severity of Illness IndexAlcohol Withdrawal SeizuresSuicidal Ideation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicinemedicineHumans030212 general & internal medicinePsychiatryeducationDepression (differential diagnoses)Agededucation.field_of_studyAlcohol Use Disorders Identification Testbusiness.industryDepressionAlcohol dependenceMiddle Agedmedicine.diseaseAlcoholismCross-Sectional StudiesNeurologyQuality of LifeFemaleNeurology (clinical)business030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Clinical Predictors of Response to Magnetic Seizure Therapy in Depression

2019

Objectives Magnetic seizure therapy (MST) is a novel convulsive brain stimulation method in clinical testing, which is used as an alternative for electroconvulsive therapy in patients with treatment-resistant depression (TRD). Preliminary studies have suggested that MST leads to fewer cognitive adverse effects than electroconvulsive therapy but has similar efficacy. However, the clinical predictors of response to MST have not been evaluated yet. This study aimed to investigate whether these predictors can be identified in patients with TRD. Methods Thirty-eight patients with TRD were included. As clinical predictors for treatment response, we used the diagnosis, sex, age, family history, an…

AdultMalemedicine.medical_specialtyAnhedoniaMagnetic Field Therapymedicine.medical_treatmentNeuroscience (miscellaneous)Depressive Disorder Treatment-Resistant03 medical and health sciences0302 clinical medicineElectroconvulsive therapyPredictive Value of TestsSeizuresInternal medicinemedicineHumansFamily historyAtypical depressionDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressionbusiness.industryHamilton Rating Scale for DepressionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomeMagnetic seizure therapyBrain stimulationAnxietyFemalemedicine.symptombusinesshuman activities030217 neurology & neurosurgeryThe Journal of ECT
researchProduct

Effects of magnetic seizure therapy on anterograde and retrograde amnesia in treatment‐resistant depression

2019

Background Electroconvulsive therapy (ECT) is the gold standard for treatment-resistant depression (TRD). However, cognitive side effects, mainly anterograde and retrograde amnesia, frequently occur. Magnetic seizure therapy (MST) is tested using more focal seizure induction. However, the suggestion MST may be more beneficial than ECT because it causes fewer amnesia have not yet been comprehensively investigated using common neuropsychological testing specifically for ECT. We aimed to examine whether MST causes anterograde and retrograde amnesia. Methods Ten patients with TRD were treated with MST (8.9 [2] treatments) at 100% machine output, a frequency of 100 Hz and 657.4 (62) pulses per t…

AdultMalemedicine.medical_specialtyAnterograde amnesiamedicine.medical_treatmentAmnesiaNeuropsychological TestsAudiologybehavioral disciplines and activitiesDepressive Disorder Treatment-ResistantExecutive Function03 medical and health sciences0302 clinical medicineElectroconvulsive therapySeizuresmental disordersmedicineHumansElectroconvulsive Therapymedicine.diagnostic_testbusiness.industryRetrograde amnesiaNeuropsychological testMiddle AgedAmnesia Anterogrademedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyMagnetic FieldsMagnetic seizure therapyBrain stimulationMental RecallAmnesia RetrogradeFemalemedicine.symptombusinesshuman activitiesTreatment-resistant depression030217 neurology & neurosurgeryDepression and Anxiety
researchProduct

Mortality in the first 30 days following incident acute symptomatic seizures.

2005

Purpose: Very little is known about short-term mortality after acute symptomatic seizure. One study found an increased mortality in the first year after acute symptomatic seizure, like mortality following acute symptomatic status epilepticus. Methods: We studied mortality in the first 30 days after an acute symptomatic seizure in two cohorts. In Washington Heights, New York City, we reviewed the medical records of all adults aged 20 years and older seen at Columbia Presbyterian Medical Center from January 1, 1990 through December 13, 1994 to identify incident acute symptomatic seizure. In Rochester, Minnesota, the medical records of all Rochester residents were reviewed to identify incident…

AdultMalemedicine.medical_specialtyPediatricsMinnesotaComorbidityCohort StudiesEpilepsyCause of DeathCase fatality ratemedicineHumansMortalityCause of deathAgedEpilepsybusiness.industryIncidence (epidemiology)IncidenceSymptomatic seizuresMiddle Agedmedicine.diseaseSurgeryStandardized mortality ratioNeurologyAcute DiseaseEtiologyFemaleNew York CityNeurology (clinical)businessCohort studyFollow-Up StudiesEpilepsia
researchProduct

Acute symptomatic seizures in cerebral venous thrombosis

2020

© 2020 American Academy of Neurology

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageInfarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineModified Rankin ScaleRisk FactorsSeizuresInternal medicinemedicineHumans030212 general & internal medicineStrokeIntracerebral hemorrhageVenous Thrombosisbusiness.industrycerebral venous thrombosisSymptomatic seizuresOdds ratioMiddle Agedmedicine.diseaseThrombosisCerebral Veins3. Good healthVenous thrombosisAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)Intracranial Thrombosisbusiness030217 neurology & neurosurgery
researchProduct